Sartorius Stedim Biotech S.A. (EPA:DIM)

Sartorius Stedim Biotech Cash Flow Statement

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	373.2	219.2	401.9	1,130	646.7
Depreciation & Amortization	318.1	301.7	236.8	181.7	141.6
Other Adjustments	175	178.8	38.1	-126.9	232.7
Change in Receivables	42.9	38.3	162.1	-65.8	-87.3
Changes in Inventories	-46.4	207.6	131.2	-217.9	-275.4
Changes in Accounts Payable	-21.4	2.8	-87.9	-68	210.3
Changes in Income Taxes Payable	-149.1	-133.5	-135.8	-221.2	-166.6
Operating Cash Flow	692.2	815.1	746.4	612.3	701.9
Operating Cash Flow Growth	-15.08%	9.20%	21.90%	-12.77%	68.37%
Capital Expenditures	-393.2	-339.8	-473.6	-430.6	-324
Purchases of Investments	-4.4	-0.1	-8.1	-	-
Payments for Business Acquisitions	-	-	-2,241	-515.6	-141.7
Other Investing Activities	-	-	-	-11.4	0.4
Investing Cash Flow	-397.7	-340	-2,723	-442	-323.6
Long-Term Debt Issued	13.3	17.3	2,649	566.8	74.2
Long-Term Debt Repaid	-334.8	-879.2	-326.4	-174.4	-79.7
Net Long-Term Debt Issued (Repaid)	-321.5	-861.9	2,323	392.4	-5.5
Issuance of Common Stock	0	1,194	0	-	-
Repurchase of Common Stock	0.2	-1.9	1.3	-3.2	0
Net Common Stock Issued (Repurchased)	0.2	1,192	1.3	-3.2	-
Common Dividends Paid	-67.1	-67.1	-132.7	-116.1	-62.7
Other Financing Activities	-154.5	-177.8	-205.3	-52.4	-9.5
Financing Cash Flow	-542.8	84.9	1,986	220.7	-77.7
Effect of Exchange Rate Changes on Cash and Cash Equivalents	-4.5	2.3	-0.3	8	4.8
Net Cash Flow	-248.3	560	9.8	-124.5	159
Free Cash Flow	299	475.3	272.8	181.7	377.9
Free Cash Flow Growth	-37.09%	74.23%	50.14%	-51.92%	46.65%
FCF Margin	10.08%	17.10%	9.83%	5.20%	13.09%
Free Cash Flow Per Share	3.07	4.91	2.96	1.97	4.10
Levered Free Cash Flow	-347.9	-648	2,304	512.5	-5.2
Unlevered Free Cash Flow	82.55	340.59	20.44	18.66	140.31

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.